WTX is rarely mutated in acute myeloid leukemia

Haematologica

Volumn 93, Issue 6, 2008, Pages 947-948

  Owen, Carolyn ^a   Virappane, Priya ^a   Alikian, Mary ^a   Stasevich, Irina ^a   Summers, Karin ^a   Lillington, Debbie ^a   Bonnet, Dominique ^b   Burnett, Alan ^c   Mills, Ken ^d   Lister, T Andrew ^a   Fitzgibbon, Jude ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

AML; Mutation; WTX

Indexed keywords

BETA CATENIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW; CANCER DIAGNOSIS; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; WTX GENE;

ADULT; CHROMOSOME ABERRATIONS; FEMALE; HEMATOPOIESIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 44949105198     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12509     Document Type: Letter

References (13)

1. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007;315:642-5.
2. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, et al. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 2007;316:1043-6.
3. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, et al. FLT3 regulates β-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007;21:2476-84.
4. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, et al. Expression of β-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006;20:1211-6.
5. Lilleberg SL, Hempel J, Durocher J, Foster D, Hartman C, Stoddard J, et al. High-throughput genetic profiling of acute myeloid leukemias: novel mutations detected in signal transduction pathway genes by a strategy utilizing endonuclease-based heteroduplex scanning and DNA sequencing. ASH Annual Meeting Abstracts 2006;108:1447a[Abstract].
6. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
7. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007;21:550-1.
8. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
9. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17.
10. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
11. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, et al. Mutational activation of the β-catenin protooncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
12. Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 1997;89:3624-35.
13. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/β-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005;24:2410-20.